Tyler Duellman1, Christopher L Warren2, Jon Matsumura3, Jay Yang4. 1. Molecular and Cellular Pharmacology Graduate Program, University of Wisconsin School of Medicine and Public Health, Madison, Wisc. 2. Proteovista LLC, Madison, Wisc. 3. Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisc. 4. Molecular and Cellular Pharmacology Graduate Program, University of Wisconsin School of Medicine and Public Health, Madison, Wisc; Department of Anesthesiology, University of Wisconsin School of Medicine and Public Health, Madison, Wisc. Electronic address: jyang75@wisc.edu.
Abstract
BACKGROUND: The natural history of abdominal aortic aneurysms (AAAs) suggests that some remain slow in growth rate whereas many develop a more accelerated growth rate and reach a threshold for intervention. We hypothesized that different mechanisms are responsible for AAAs that remain slow growing and never become actionable vs the aggressive AAAs that require intervention and may be reflected by distinct associations with genetic polymorphisms. METHODS: AAA growth rate was determined from serial imaging data in 168 control and 141 AAA patients with ultrasound or computed tomography imaging studies covering ∼5 years. Genetic polymorphisms all previously reported as showing a significant correlation with AAA with functional effects on the expression or function were determined by analysis of the genomic DNA, including angiotensin 1 receptor (rs5186), interleukin-10 (IL-10; rs1800896), methyl-tetrahydrofolate reductase (rs1801133), low-density lipoprotein receptor-related protein 1 (LRP1; rs1466535), angiotensin-converting enzyme (rs1799752), and several matrix metalloproteinase 9 (MMP-9) single nucleotide polymorphisms. RESULTS: Of the AAA patients, 81 were classified as slow AAA growth rate (<3.25 mm/y) vs 60 with aggressive AAA growth rate (>3.25 mm/y, those presenting with a rupture, or those with maximal aortic diameter >5.5 cm [male] or >5.0 cm [female]). Discriminating confounds between the groups were identified by logistic regression. Analyses identified MMP-9 p-2502 single nucleotide polymorphism (odds ratio [OR], 0.54; 95% confidence interval [CI], 0.31-0.94; P = .029) as a significant confound discriminating between control vs slow-growth AAA, MMP-9 D165N (OR, 0.49; 95% CI, 0.26-0.95; P = .035) and LRP1 (OR, 4.99; 95% CI, 1.13-22.1; P = .034) between control vs aggressive-growth AAAs, and methyltetrahydrofolate reductase (OR, 2.99; 95% CI, 1.01-8.86; P = .048), MMP-9 p-2502 (OR, 2.19; 95% CI, 1.05-4.58; P = .037), and LRP1 (OR, 4.96; 95% CI, 1.03-23.9; P = .046) as the statistically significant confounds distinguishing slow-growth AAAs vs aggressive-growth AAAs. CONCLUSIONS: Logistic regression identified different genetic confounds for the slow-growth and aggressive-growth AAAs, indicating a potential for different genetic influences on AAAs of distinct aggressiveness. Future logistic regression studies investigating for potential genetic or clinical confounds for this disease should take into account the growth rate and size of the AAA to better identify confounds likely to be associated with aggressive AAAs likely to require intervention.
BACKGROUND: The natural history of abdominal aortic aneurysms (AAAs) suggests that some remain slow in growth rate whereas many develop a more accelerated growth rate and reach a threshold for intervention. We hypothesized that different mechanisms are responsible for AAAs that remain slow growing and never become actionable vs the aggressive AAAs that require intervention and may be reflected by distinct associations with genetic polymorphisms. METHODS: AAA growth rate was determined from serial imaging data in 168 control and 141 AAA patients with ultrasound or computed tomography imaging studies covering ∼5 years. Genetic polymorphisms all previously reported as showing a significant correlation with AAA with functional effects on the expression or function were determined by analysis of the genomic DNA, including angiotensin 1 receptor (rs5186), interleukin-10 (IL-10; rs1800896), methyl-tetrahydrofolate reductase (rs1801133), low-density lipoprotein receptor-related protein 1 (LRP1; rs1466535), angiotensin-converting enzyme (rs1799752), and several matrix metalloproteinase 9 (MMP-9) single nucleotide polymorphisms. RESULTS: Of the AAA patients, 81 were classified as slow AAA growth rate (<3.25 mm/y) vs 60 with aggressive AAA growth rate (>3.25 mm/y, those presenting with a rupture, or those with maximal aortic diameter >5.5 cm [male] or >5.0 cm [female]). Discriminating confounds between the groups were identified by logistic regression. Analyses identified MMP-9 p-2502 single nucleotide polymorphism (odds ratio [OR], 0.54; 95% confidence interval [CI], 0.31-0.94; P = .029) as a significant confound discriminating between control vs slow-growth AAA, MMP-9 D165N (OR, 0.49; 95% CI, 0.26-0.95; P = .035) and LRP1 (OR, 4.99; 95% CI, 1.13-22.1; P = .034) between control vs aggressive-growth AAAs, and methyltetrahydrofolate reductase (OR, 2.99; 95% CI, 1.01-8.86; P = .048), MMP-9 p-2502 (OR, 2.19; 95% CI, 1.05-4.58; P = .037), and LRP1 (OR, 4.96; 95% CI, 1.03-23.9; P = .046) as the statistically significant confounds distinguishing slow-growth AAAs vs aggressive-growth AAAs. CONCLUSIONS: Logistic regression identified different genetic confounds for the slow-growth and aggressive-growth AAAs, indicating a potential for different genetic influences on AAAs of distinct aggressiveness. Future logistic regression studies investigating for potential genetic or clinical confounds for this disease should take into account the growth rate and size of the AAA to better identify confounds likely to be associated with aggressive AAAs likely to require intervention.
Authors: David Sidloff; Philip Stather; Nikesh Dattani; Matthew Bown; John Thompson; Robert Sayers; Edward Choke Journal: Circulation Date: 2013-11-18 Impact factor: 29.690
Authors: Felix J V Schlösser; Marco J D Tangelder; Hence J M Verhagen; Geert J M G van der Heijden; Bart E Muhs; Yolanda van der Graaf; Frans L Moll Journal: J Vasc Surg Date: 2008-04-28 Impact factor: 4.268
Authors: Alban Gaultier; Sanja Arandjelovic; Sherry Niessen; Cheryl D Overton; MacRae F Linton; Sergio Fazio; W Marie Campana; Benjamin F Cravatt; Steven L Gonias Journal: Blood Date: 2008-03-27 Impact factor: 22.113
Authors: Matthew J Bown; Geraint M Lloyd; Rebecca M Sandford; John R Thompson; Nicholas J M London; Nilesh J Samani; Robert D Sayers Journal: J Vasc Surg Date: 2007-10 Impact factor: 4.268
Authors: Mickey M Martin; Jessica A Buckenberger; Jinmai Jiang; Geraldine E Malana; Gerard J Nuovo; Maqsood Chotani; David S Feldman; Thomas D Schmittgen; Terry S Elton Journal: J Biol Chem Date: 2007-06-22 Impact factor: 5.157
Authors: S G Thompson; L C Brown; M J Sweeting; M J Bown; L G Kim; M J Glover; M J Buxton; J T Powell Journal: Health Technol Assess Date: 2013-09 Impact factor: 4.014
Authors: Thomas Schmitz-Rixen; M Keese; M Hakimi; A Peters; D Böckler; K Nelson; R T Grundmann Journal: Langenbecks Arch Surg Date: 2016-03-21 Impact factor: 3.445
Authors: Menno E Groeneveld; Jorn P Meekel; Sidney M Rubinstein; Lisanne R Merkestein; Geert Jan Tangelder; Willem Wisselink; Maarten Truijers; Kak Khee Yeung Journal: J Am Heart Assoc Date: 2018-06-30 Impact factor: 5.501